WHAT ARE CLINICAL TRIALS?
Clinical trials are research studies that test new approaches to treatment. They help doctors determine if a new treatment is safe, effective, and potentially better than current options. Participating in a clinical trial can offer patients access to cutting-edge treatments and the chance to contribute to advancements in brain cancer care.
You can also learn more through these resources:
Clinical Trial Navigation through Carebox Connect!
Hope4ATRT is proud to partner with Carebox, a free and confidential service that simplifies the search for Atypical Teratoid Rhabdoid Tumor (ATRT) clinical trials.
Patients, caregivers, and healthcare professionals can easily create a profile by answering a few questions. Carebox then matches you with relevant ATRT clinical trials that might be a good fit, empowering you to make informed decisions about your care.
Important to Know:
-
Carebox protects your privacy and does not share your information with trial sites.
-
Matching with a trial doesn't guarantee enrollment, and participation is always voluntary.
-
You can stop using Carebox at any time.
Start your search for potential ATRT clinical trials today!
Open Clinical Trials
Selinexor in People with Wilms Tumors and Other Solid Tumors
Purpose of this clinical trial:
The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, or another solid tumor that makes a higher than normal amount of XPO1 or has genetic changes that increase the activity of XP01.
Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Purpose of this clinical trial:
The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establish the maximum-tolerated dose) and evaluate the occurrence of dose-limiting toxicities (DLTs) following single weekly or multiple-day weekly dose regimens of single-agent, oral ONC206 in patients with recurrent, primary central nervous system (CNS) neoplasms.
GAIL-B: C7R-GD2.CAR T Cells for Patients with GD2-expressing Brain Tumors
Purpose of this clinical trial:
The purpose of this study is to investigate the effectiveness of a new gene therapy approach using engineered T cells to treat patients with diffuse midline glioma, high-grade glioma, diffuse intrinsic pontine glioma, medulloblastoma, or other rare brain cancers that express GD2.
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients with Primary CNS Tumors
Purpose of this clinical trial:
The purpose of this study is to find: 1) the largest dose of Loc3CAR T cells that is safe to give patients with B7-H3–positive brain tumors; 2) the side effects of Loc3CAR T cells; 3) the effect Loc3CAR T cells have on brain tumors. This trial will help scientists better understand how the immune system fights this kind of tumor. What we learn from this study could help us create better treatments.
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
Purpose of this clinical trial:
This phase I/II trial studies how well tiragolumab and atezolizumab works when given to children and adults with SMARCB1 or SMARCA4 deficient tumors that have either come back (relapsed) or do not respond to therapy (refractory). SMARCB1 or SMARCA4 deficiency means that tumor cells are missing the SMARCB1 and SMARCA4 genes, seen with some aggressive cancers that are typically hard to treat. Immunotherapy with monoclonal antibodies, such as tiragolumab and atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
AflacST1502: A Phase II Study of Sirolimus in Combination with Metronomic Chemotherapy in Children with Recurrent and/or Refractory Solid and CNS Tumors
Purpose of this clinical trial:
This study aims to determine the efficacy of daily sirolimus and celecoxib, with low dose etoposide alternating with cyclophosphamide for pediatric participants with relapsed or refractory tumors.
BrainChild-04: Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy for Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors
Purpose of this clinical trial:
The BrainChild-04 study is investigating Seattle Children’s Therapeutics’ first CAR T-cell product that targets four antigens simultaneously: B7-H3, EGFR806, HER2 and IL13-zetakine. This is the first known CAR T-cell product in the world to target four antigens at the same time by delivering CAR T cells directly to the brain.
TAZNI: A Phase I/II Combination Trial of Tazemetostat with Nivolumab and Ipilimumab for Children with INI1-Negative or SMARCA4-Deficient Tumors
Purpose of this clinical trial:
This research study involves a combination of three drugs given together as a possible treatment for malignant rhabdoid tumor, atypical teratoid rhabdoid tumor, epithelioid sarcoma, chordoma or other tumors that are deficient in one of two possible proteins, either INI-1 (SMARCB1) or SMARCA4.
PNOC025: Magrolimab in Children and Adults with Recurrent or Progressive Malignant Brain Tumors
Please note, this study is currently suspended: FDA Partial Clinical Hold
Purpose of this clinical trial:
The goal of this study is to test the safety and efficacy of magrolimab in children and adults with recurrent or progressive malignant brain tumors. Magrolimab is a novel antibody anticancer therapeutic agent targeting a certain protein called CD47. Binding of magrolimab to CD47 on target malignant cells blocks the "don't eat me" signal by cancer cells and enhances tumor cell phagocytosis.
MEMMAT: Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma and ATRT
Purpose of this clinical trial:
The goal of this study is to provide additional therapy options for children with recurrent or progressive medulloblastoma, ependymoma and ATRT, for whom no known curative therapy exists, by prolonging survival while maintaining good quality of life. The primary objective of the MEMMAT trial is to evaluate the activity of this multidrug antiangiogenic approach in previously treated children and young adults
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Please note, this study is not currently recruiting patients
Purpose of this clinical trial:
This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested.
ABOUT ATRT
ATRT is a very rare, fast-growing tumor of the brain and spinal cord. The disease commonly affects children age 3 or younger but can also affect older children and adults. Learn more.
ABOUT HOPE4ATRT
Drs. Kosj and Jaymi Yamoah started Hope4ATRT after walking through their own cancer journey as a family. In 2015 their almost three-year-old son, Zion, was diagnosed with a rare and aggressive form of brain cancer known as Atypical Teratoid Rhabdoid Tumor (ATRT). Even as an oncologist himself, Dr. Yamoah was dismayed to learn how limited resources were for this rare disease. After the devastating loss of Zion, his parents were compelled to help fund innovative research, and be a resource for families in the fight against ATRT.
Hope4ATRT's mission is two-fold:
-
to direct resources to parents of children with ATRT
-
to raise funding for innovative research specifically for ATRT
To learn more visit Hope4atrt.org , and connect on Facebook , Instagram and YouTube.